CRGX News
Archived Headlines
- Cancer biotech CARGO Therapeutics sets terms for $300 million IPO 11/06/23
- US IPO Week Ahead: Reinsurer Hamilton Group and biotech CARGO Therapeutics plot next major IPOs amid difficult market 11/03/23
- US IPO Weekly Recap: Big launches and new filings keep the IPO market moving 10/20/23
- Cancer biotech CARGO Therapeutics files for a $100 million IPO 10/20/23
Renaissance Capital's November IPO Market Update
Eleven US IPOs raised a combined $708 million in November, well below the month's historical 10-year average (16 IPOs, $4.2B). Deal flow was led by three sizable issuers, and remaining activity came from smaller companies, all of which raised $33 million or less...read more
US IPO Weekly Recap: Reinsurance and CAR T therapies lead a 3 IPO week
Three IPOs and two SPACs debuted this week, while the pipeline got a boost from a flurry of initial filings. Oncology biotech CARGO Therapeutics (CRGX) priced at the bottom of the range to raise $281 million at a $611 million market cap. The...read more
Cancer biotech CARGO Therapeutics prices IPO at $15, the low end of the range
CARGO Therapeutics, a Phase 2 biotech developing CAR T cell therapies for cancer, raised $281 million by offering 18.8 million shares at $15, the low end of the range of $15 to $17. CARGO Therapeutics' lead program, CRG-022, is an autologous CD22...read more
CAR T cancer biotech CARGO Therapeutics targets a $300 million IPO, as it seeks to overcome weak trading from recent biotech listings
Another large biotech IPO has joined the calendar, seeking to buck the trend of mostly negative returns from recent listings in the industry. CARGO Therapeutics (CRGX) launched on Monday, planning to raise $300 million in what would be the...read more